However, the Aβ hypothesis continues to be the major focus of AD therapeutic intervention, although new developments in the disease indicate that this is not a single-symptom disease, and that other pathways such as tau aggregation, neuroinflammation, and neurotransmitter imbalance also need to be targeted. Here, MAPT is linked to Alzheimer disease.